Supernus says FDA grants tentative OK to drug

Published



ROCKVILLE, Md. (AP) — Shares of Supernus Pharmaceuticals Inc. more than doubled in price Tuesday after the specialty drugmaker said regulators have moved closer to granting final approval to its potential epilepsy treatment Trokendi XR.

The Rockville, Md., company said the Food and Drug Administration gave tentative approval for the once-daily treatment and told Supernus it would require no additional clinical trials.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.